CytoGenix, Inc. Announces a New Product in Development
Houston, TX, (March 31, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces the preclinical development of CY403 a antibacterial compound that is specific against all strains of Staphylococcus aureus, especially resistant strains such as MRSA - Methicillin-resistant and VRSA - Vancomycin- resistant, popularly referred to as "superbugs".
The incidence of infection by resistant bacteria is increasing rapidly and is most common in at-risk hospital patients. In a report titled "Proportion of S. aureus Nosocomial Infections Resistant to Oxacillin (MRSA) Among Intensive Care Unit Patients, 1989-2003", the U.S. Centers for Disease Control and Prevention - CDC shows that the proportion of ICU patients with resistant staph infections has grown from 30% in 1989 to 60% in 2003.
Dr. Yin Chen, CytoGenix' Vice President and Chief Scientific Officer commented, "The introduction of CY403 into the preclinical product development phase within three months after target discovery and validation demonstrates the true value of our gene silencing technology. We have the capability to move very efficiently from discovery to product candidate in a matter of a few months."
"Recent laboratory studies show that this compound rapidly kills MRSA and prevents further growth. Evidence shows that this compound is a powerful bacteriacidal as well as a bacteriastatic agent against MRSA. Further studies will confirm these capabilities in animal and human trials." added Dr. Chen.
AI
